Transcranial Ultrasound in Clinical SONothrombolysis

• Status: Terminated
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImaRx Therapeutics
• Treatments: Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

• Acute ischemic stroke

• Occlusion demonstrated by transcranial Doppler ultrasound

• Eligible for tPA

Exclusion Criteria:

• Right to left cardiac shunt

• Moderate to severe COPD

• Uncontrolled hypertension